Trials / No Longer Available
No Longer AvailableNCT05100134
Managed Access Programs for LDK378, Ceritinib
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 1 Year
- Healthy volunteers
- Not accepted
Summary
The purpose of this registration is to list Managed Access Programs (MAPs) related to LDK378, Ceritinib.
Detailed description
CLDK378A2401 - No longer available - Managed Access Program (MAP) to provide access to Ceritinib, for ALK Positive Tumors. CLDK378A2402 - No longer available - An open-label, multi-center, Expanded Treatment Protocol (ETP) of oral LDK378 in adult patients with non-small cell lung cancer (NSCLC) characterized by ALK positivity. CLDK378A2003M - No longer available- Managed Access Program (MAP) Cohort Treatment Plan CLDK378A2003M to provide access to LDK378 (ceritinib), for ALK-Positive Tumor Pediatric Patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ceritinib | Patients receive ceritinib |
Timeline
- First posted
- 2021-10-29
- Last updated
- 2026-04-01
Source: ClinicalTrials.gov record NCT05100134. Inclusion in this directory is not an endorsement.